Aegera is active in seeking development partners for its drug candidates. We will consider and evaluate global and regional partnership opportunities that enhance the value of these programs through a combination of complementary products, technologies and expertise, financial commitment, large-scale clinical trial management expertise, and commercial capabilities.

In-Licensing

As part of its corporate business development activities, Aegera has established an aggressive in-licensing strategy and is actively seeking high quality development candidates that meet defined criteria to extend and complement its internal pipeline of novel targeted therapeutics.

Aegera In-Licensing Criteria

Aegera employs a stringent screening process using clear scientific, medical and economic metrics to evaluate opportunities according to the following criteria. Aegera will nonetheless be opportunistic when presented with opportunities failing to strictly meet these defined criteria.

• Small molecules (including peptidomimetics and small stable peptides) and therapeutic monoclonal antibodies with strong IP coverage, addressing unmet medical needs in oncology, pain, and inflammatory/autoimmune diseases;
• Direct activity on a known and biologically validated target;
• Primary indication that will allow a meaningful clinical readout in a Phase 2 study;
• Lead/preclinical stage compounds (max. 18 months from IND filing) up to Phase 3 (with an emphasis on proof of principle);
• Licensor must be open to MTA as a condition to in-licensing;
• Market potential of $100M or greater;
• North American rights required, Worldwide preferred;
• Patent protected (composition of matter and uses);
• Competitive advantage(s) that provide a sustainable edge over existing and potential competitors and alternative treatments.